US2022208327A1PendingUtilityA1
Methods Of Treating Overweight And Obesity
Assignee: NALPROPION PHARMACEUTICALS LLCPriority: Jun 6, 2012Filed: Oct 4, 2021Published: Jun 30, 2022
Est. expiryJun 6, 2032(~5.9 yrs left)· nominal 20-yr term from priority
A61P 9/04A61P 3/04A61P 9/00G16H 20/10A61K 31/137G01G 19/4146G09B 5/065A61K 31/485A61P 9/10G09B 19/0092A61K 2300/00
72
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The present disclosure relates to compositions, kits, uses, systems and methods for treating overweight and obesity using naltrexone plus bupropion, preferably in combination with a comprehensive web-based and/or telephone-based weight management program, and preferably in subjects at increased risk of adverse cardiovascular outcomes.
Claims
exact text as granted — not AI-modified1 . A method of treating a subject at increased risk of an adverse cardiovascular outcome comprising for overweight or obesity:
identifying an overweight or obese subject at increased risk of an adverse cardiovascular outcome; and administering to said subject a therapeutically effective amount of sustained release naltrexone, or a pharmaceutically acceptable salt thereof, and sustained release bupropion, or a pharmaceutically acceptable salt thereof.
2 - 35 . (canceled)Join the waitlist — get patent alerts
Track US2022208327A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.